Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PSNL - Personalis Inc


IEX Last Trade
5.45
-0.350   -6.422%

Share volume: 1,336,948
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$5.80
-0.35
-6.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
21%
Profitability 2%
Dept financing 10%
Liquidity 75%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-8.88%
1 Month
74.36%
3 Months
315.27%
6 Months
272.60%
1 Year
231.71%
2 Year
67.38%
Key data
Stock price
$5.45
P/E Ratio 
-3.54
DAY RANGE
N/A - N/A
EPS 
-$1.62
52 WEEK RANGE
$0.89 - $7.20
52 WEEK CHANGE
$1.94
MARKET CAP 
288.726 M
YIELD 
N/A
SHARES OUTSTANDING 
53.075 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
2.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,246,455
AVERAGE 30 VOLUME 
$1,700,083
Company detail
CEO: John West
Region: US
Website: http://www.personalis.com/
Employees: 428
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.

Recent news